Tumor Model Hub

Accelerate Oncology Drug Development with Proven Tumor Models

From model selection to in vivo efficacy, PK/PD, and biomarker analysis - we deliver reproducible data for confident decision-making.

Learn More
3D tumor model illustration on a blue gradient background for oncology drug development services.
Preclinical Tumor Models for Oncology Drug Discovery

Alfa Cytology provides in vivo tumor models and pharmacology services to support your drug development programs from target validation to efficacy studies.

Learn More
3D tumor cell illustrations on a blue gradient background for preclinical oncology drug discovery services.
Tumor Model Hub - by Alfa Cytology

Comprehensive in vivo models for oncology research: CDX (mouse/rat), orthotopic, metastatic, syngeneic, induced, drug-resistant, PDX, humanized, and Ba/F3-based engineered cell lines.

Learn More
3D antibody structure illustration on a blue gradient background for tumor model research services.
In Vivo Tumor Models Services & Platforms Why Choose Us FAQs

Alfa Cytology: Your Partner in Preclinical Tumor Model Development

Alfa Cytology provides comprehensive tumor models (CDX, PDX, syngeneic, orthotopic, metastatic, and more) and in vivo efficacy services, empowering clients to accelerate targeted oncology drug development.

About

Scientific
Excellence

About

Customized
Solutions

About

Collaborative
Approach

About

Data
Security

Scientist presenting Alfa Cytology cancer research services in a video.

In Vivo Tumor Models

About

CDX Mouse Model

Human tumor cell lines engrafted in immunodeficient mice; rapid, reproducible, and widely used for efficacy screening.
About

CDX Rat Model

Larger body size enables serial sampling, surgical interventions, and advanced imaging for PK/PD studies.
About

Orthotopic Model

Tumor cells implanted into the native organ; recapitulates clinical tumor microenvironment and metastatic progression.
About

Syngeneic Model

Mouse tumor cells in immunocompetent hosts; ideal for immuno-oncology and combination therapy evaluation.
About

Metastatic Model

Spontaneous or experimental metastasis (bone, brain, liver, lung); supports study of tumor dissemination and anti-metastatic agents.
About

Induced Model

Chemically induced tumors (AOM/DSS, DEN, DMBA, BBN); recapitulates inflammation-driven carcinogenesis and prevention studies.
About

Drug-Resistant Model

Acquired resistance to standard-of-care agents (tamoxifen, cisplatin, osimertinib, imatinib); enables mechanism studies and next-line therapy testing.
About

PDX Model

Patient-derived tumor fragments in immunodeficient mice; preserves histological and genetic heterogeneity for precision medicine.
About

Humanized Model

Mice engrafted with human immune components; enables evaluation of human-specific immunotherapies.

Comprehensive Services & Platforms

Laboratory mouse in a research facility for in vivo pharmacology and tumor growth inhibition studies.

In Vivo Pharmacology

Tumor growth inhibition (TGI) studies

Survival analysis
Researcher handling samples with a pipette for PK/PD drug concentration analysis in a laboratory setting.

PK/PD

Drug concentration measurement in plasma and tumor tissue
Automated laboratory equipment for biomarker analysis and omics processing in a research facility.

Biomarker Services

IHC/IF

Flow cytometry

NGS / omics analysis
Advanced laboratory workstation with imaging display for small animal research and combination therapy studies.

Specialized Platforms

Small animal imaging (BLI / FMT / MRI)

Combination therapy study design

Tailored Tumor Models for Oncology Drug Discovery

Oncology-Focused

Deep expertise in cancer biology and in vivo pharmacology, not general CRO work.

Rigorously Validated

Every model STR-authenticated, mycoplasma-free, and histologically verified.

Business professional interacting with a digital network interface for oncology drug discovery partnership services.

Tailored Study Design

Customized from model selection to dosing and endpoints for your specific program.

Transparent Partnership

Full raw data access and direct communication with our scientific team.

Frequently Asked Questions

Q1: What types of tumor models do you offer?

A1: We provide a broad range of in vivo models, including CDX (mouse and rat), orthotopic, metastatic, syngeneic, chemically induced, drug-resistant, PDX, and humanized mouse models.

Q2: How do you ensure model quality and data reproducibility?

A2: All models are STR-authenticated, routinely tested for mycoplasma, and histologically verified. Studies follow standardized protocols with full documentation.

Q3: Can you design a customized study for my specific target or molecule?

A3: Yes. We tailor study designs from model selection, dosing regimen, and endpoints to biomarker analysis, based on your molecule type (small molecule, antibody, ADC, etc.) and research questions.

Q4: What data and reports will I receive after a study?

A4: You receive individual animal data, raw tumor growth curves, body weight records, pathology images (if applicable), and a comprehensive study report with statistical analysis.

Q5: Do you provide support for regulatory submissions such as an IND?

A5: We provide GLP-like study documentation and audit-ready reports that can support IND-enabling packages. Please contact us to discuss specific requirements.

The Oncology Resource Center

Alfa Cytology company profile cover featuring laboratory research.

About Alfa Cytology

As a committed preclinical research service provider focused on cancer, Alfa Ctytology’s one-stop drug discovery services and a range of technology platforms will address the diverse needs of our clients, guaranteeing innovative and effective research results.

Learn More
Targeted radionuclide drug conjugation service overview.

Your Trusted Partner in Radionuclide Drugs Conjugation (RDC) Services

Alfa Cytology delivers one-stop RDC drug-development services, covering target validation, conjugation chemistry, analytical profiling, and preclinical research under a unified workflow.

Learn More
One-stop preclinical cancer research services cover image.

One-stop Preclinical Services for Cancer Research

At Alfa Cytology, we offer a comprehensive suite of preclinical services tailored to advance cancer research and drug development. Our one-stop preclinical platform provides end-to-end solutions, from disease modeling and diagnostic development to therapeutic evaluation - all under one roof.

Learn More
Humanized antibody mouse workflow for single B cell antibody discovery.

Humanized Antibody Mouse Plus Single B Cell Technology for Antibody Discovery

Single B cell technology has emerged as a powerful method for discovering and developing antibodies, particularly in the context of cancers like bladder cancer.

Learn More
Guide to choosing in vivo models for cancer immunotherapy studies.

How to Select in Vivo Model for Cancer Immunotherapy Efficacy Assessment?

The landscape in cancer immunotherapy has undergone profound changes since its early beginnings up through the rapid advances happening today. The current drug development pipeline consists of thousands of cancer immunotherapies and therapy combinations, many of which are being evaluated in clinical trials.

Learn More
Preclinical cancer modeling and mouse study design cover.

Designing Your Preclinical Cancer Modeling Mouse Studies

The United Science Group successfully hosted the 2024 International Conference on Cancer Research and Development (Cancer R&D 2024) from November 18-20, bringing together nearly a thousand attendees to explore major advances in cancer research.

Learn More
Important Links
Get In Touch
USA

Copyright © 2026 Alfa Cytology. All rights reserved.